HAYA Therapeutics’ Post

Eric Adam Joins HAYA Therapeutics as Chief Operating Officer Learn more & get our take 👇 https://lnkd.in/gebzDCkY “Eric brings a wealth of biopharma expertise to oversee core operational functions including business development and strategic collaborations, human resources, finance, IT, communications and quality assurance. His career spans scientific and entrepreneurial roles in the pharmaceutical industry, biotechnology, medical device companies and significant contributions in the non-profit arena, which will help as we bring our first program, HTX-001 into the clinic. We welcome Eric to the HAYA family.” — Samir Ounzain, Ph.D., Co-founder and CEO at HAYA Therapeutics “I thrive on driving cultural shifts, fostering innovation, and boosting team performance to deliver successful portfolios. At HAYA I aim to translate complex research into clear priorities and decisions at the C-level keeping the bigger picture – patients and the pipeline – in mind.” — Eric Adam, Ph.D., Chief Operating Officer at HAYA Therapeutics #therapeutics #leadership #SoHCNews

In pursuing clinical research innovation, smaller biopharma companies often face a different set of challenges than larger pharma. Lacking the extensive resources and unique personnel functions of large pharmaceutical organizations, they must navigate tighter budgets and limited staffing. Yet, precisely, those constraints are what push many small biopharma to be more agile, inventive, and resilient. On May 20th at 12pm EST, join ProofPilot and Yonalink as we hear these stories of resilience, inventiveness, and agility firsthand. I can't express enough gratitude to these three leading women in biopharma for sharing their stories of derisking innovation to compete with powerhouse pharma teams: ▶ Erin O'Boyle, VP of Clinical Operations at Rezolute, Inc. ▶ Joann Peters, COO at Geneos Therapeutics ▶ Meraf Eyassu, Executive Director of Clinical Operations at Terns Pharmaceuticals Registration is in the links! 👇

#CRGEW2024 | 💊 Into the Clinical Path 💊 Yesterday, we heard from Héctor Pérez Montoyo, COO of Ability Pharmaceuticals, SA, a clinical-stage biopharmaceutical company developing therapies to harness autophagy for the selective targeting of cancers such as endometrial and pancreatic. Hector described the journey of their clinical candidate molecule, ABTL0812, and the hurdles faced in translating a preclinical candidate drug molecule into the clinical path. Here are some key takeaways from Hector’s talk: 💰 Varied funding sources: A biotech startup/scale-up can fund it’s work through many revenue streams, not just VC investments, but through crowdfunding and public grants. ☎ Relationships with regulatory agencies: Hector described that the relationship with regulatory agencies should be viewed as collaborative and, in their experience, the dialogue with the FDA/EMA has been open where they are eager to guide. It does not have to be a formal submission of a regulatory dossier, but a constant conversation! 🤝 Collaboration is key: as you move from the preclinical to clinical stages funding demands increase and as well as demands on the evidence you must produce, not to mention considerations around CMC. Hector stressed that working with experts and building a good network is key to pushing a biotech drug discovery project forward. Thank you, Hector, for sharing your experiences moving into the clinical path. #CRGEW2024 #CRGBBS2024 #entrepeneurship #IntoTheClinicalPath

🔔 Breaking News in Pharma: Eli Lilly Acquires Morphic Therapeutic for $3.2 Billion! 💊 https://lnkd.in/grVEh6XR Eli Lilly and Company (NYSE: LLY) has just finalized a landmark deal, acquiring Morphic Therapeutic, Inc. (NASDAQ: MORF) for a staggering $3.2 billion. This strategic acquisition is set to significantly enhance Lilly's portfolio, particularly in the realms of autoimmune diseases and fibrosis treatments. 📈 Key Deal Metrics: Deal Value: $3.2 Billion (all-cash transaction) Target Company: Morphic Therapeutic, a leader in oral integrin therapies Expected Closing: End of Q3 2024 Strategic Fit: Expands Lilly's autoimmune and fibrosis treatment pipeline Synergies: Combines Lilly’s R&D prowess with Morphic’s innovative integrin biology 🌟 Why This Matters: Enhanced Treatment Options: The integration of Morphic’s advanced oral integrin therapies will provide new, effective treatments for autoimmune diseases and chronic inflammatory conditions. Accelerated Research: Morphic’s expertise in integrin inhibitors will complement and accelerate Lilly’s fibrosis research efforts, addressing critical unmet medical needs. Innovative Collaborations: The merger will foster a collaborative environment, leveraging both companies’ strengths to drive scientific discovery and therapeutic advancements. 📣 Leadership Insights: David A. Ricks, CEO of Eli Lilly, emphasizes, "This acquisition reinforces our commitment to investing in innovative science and delivering life-changing treatments to patients worldwide." Praveen Tipirneni, CEO of Morphic Therapeutic, adds, "Joining forces with Lilly enables us to accelerate our pipeline development and bring transformative therapies to patients more rapidly." 🔗 Read More: For more comprehensive information related to this M&A transaction, please visit the Deal Metrics page here: https://lnkd.in/gQr2RxbB Stay tuned for more updates on this exciting development and its impact on the pharmaceutical industry. 🚀 #PharmaNews #EliLilly #MorphicTherapeutic #Acquisition #Biotech #HealthcareInnovation #DrugDevelopment #AutoimmuneDisease #Fibrosis #IntegrinTherapies

The #IPO market in the #biotech sector had a promising start in the first quarter of 2024, with several companies deciding to go public. Additionally, larger biotech companies have strategically acquired smaller yet significant late-stage companies through M&A. This activity indicates a dynamic landscape in the life sciences industry, where new entrants and established players are actively shaping the market. In a remarkable move, Gilead Sciences acquired CymaBay Therapeutics for $4.43 billion in February, demonstrating its strategic efforts to strengthen its position in the #biopharmaceutical market and transform the treatment landscape for people with primary biliary cholangitis. This acquisition is part of a more significant trend in the industry, as seen with Novartis's acquisition of cancer specialist MorphoSys for $2.77 billion and AstraZeneca's $2.41 billion investment in Fusion Pharmaceuticals. These M&As are a testament to the ongoing trend of consolidation and strategic partnerships within the biotech industry as companies strive to expand their portfolios and capabilities. Other notable M&As include: - Johnson & Johnson acquired Ambrx for approximately $2.0 billion - Sanofi to acquire Inhibrx, Inc. for $1.7 billion - GSK acquired Aiolos Bio for $1 billion - Novo Nordisk to acquire Cardior Pharmaceuticals for $1.1 billion Compass Executives #lifesciences #biotechIPO #biotechdeals #mergersandacquisitions #venturecapital

Thoughts on this? >> BioCentriq names ex-Resilient exec as new CEO; Sanofi, AstraZeneca boost Beyfortus production >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #healthcare #pharmaceutical #biotech #productmarketing

Thoughts on this? >> BioCentriq names ex-Resilient exec as new CEO; Sanofi, AstraZeneca boost Beyfortus production >> Comment below! >>> lqventures.com #strategy #competitiveintelligence #marketing #pharma #productmarketing #biotech #pharmaceutical #healthcare

Company Spotlight: Apollo Therapeutics 📣 Founded:  Founded in 2016 by Dr. Richard Mason (CEO). 📣 Specialized In:  Apollo Therapeutics is a portfolio biopharmaceutical company that focuses on translating cutting-edge medical research into innovative medicines. Utilizing a hub-and-spoke operational model, Apollo collaborates with leading academic institutions to discover and develop new therapeutic programs. The company has built a broad and diversified pipeline consisting of over 20 programs targeting major commercial markets and is committed to addressing unmet medical needs through high-quality science. 📣 Funding:  Apollo recently closed a $226.5 million financing round, significantly augmenting the $195 million previously raised. This funding will be instrumental in advancing its clinical programs and supporting ongoing drug discovery efforts. Key Investors:  ➡ Patient Square Capital (lead investor)  ➡ M&G plc  ➡ Rock Springs Capital #BiopharmaInnovation #HealthcareInvestment #DrugDevelopment #Pharma #InnovativeTherapies    

Gilead Sciences and Genesis Therapeutics Partner on AI-Driven Drug Discovery - HIT Consultant Summary: Gilead Sciences and Genesis Therapeutics have joined forces to leverage AI in drug discovery, aiming to revolutionize the pharmaceutical industry. The partnership focuses on accelerating the development of innovative treatments through advanced technology and data analysis. Key areas of collaboration include AI algorithms, machine learning models, and predictive analytics to enhance drug discovery processes. This strategic alliance between Gilead and Genesis signifies a significant step towards integrating AI into healthcare research and development, paving the way for groundbreaking advancements in medicine. #Gilead #Genesis #AI #DrugDiscovery #HealthcareIT Headings: 1. Introduction to Gilead Sciences and Genesis Therapeutics Partnership #Gilead #Genesis #Partnership 2. Leveraging AI in Drug Discovery #AI ai.mediformatica.com #gilead #collaboration #platform #aiplatform #drugdevelopment #advanced #biopharmaceutical #drugdiscovery #edge #partnership #strategic #digitalhealth #healthit #healthtech #healthcaretechnology @MediFormatica (https://buff.ly/3XlCXlW)

Stories making headlines today in the biopharma industry: AbbVie's CEO, Rick Gonzalez, is set to retire in July, handing over to Robert Michael, the firm's current president and chief operating officer. This transition, following Gonzalez's successful stewardship over top-selling drug, Humira, presents a unique scenario in a sector known for favoring external hires for leadership roles. In other pharma news, giants Bristol Myers Squibb, Novartis, Novo Nordisk, and J&J’s Janssen are collectively challenging laws under the Inflation Reduction Act in court, while Bayer's CEO Bill Anderson is set to cut dividends by a staggering 95% in an ambitious turnaround effort. Sanofi's Genzyme is facing a revived lawsuit over access to its Fabry disease drug, while Takeda takes on a new corporate restructuring phase to raise its US profile. Meanwhile, a Chinese API manufacturer faces stern warnings over QC concerns from the FDA. Resilience is investing a significant $225M to widen its manufacturing capacity in Cincinnati, while WuXi AppTec's US subsidiary will handle manufacturing of Iovance’s TIL Therapy. In late-stage clinical trial findings, AstraZeneca’s drug, Tagrisso, showed promise in lung cancer treatment, reshuffling the biotech's $100 billion club. Furthermore, FDA has approved Iovance's novel cell therapy for melanoma, the first of its kind based on tumor-infiltrating lymphocytes, marking another giant leap for cancer therapeutics. #pharma #biotech #topstories #biodatastudio